What did we learn after the 2020 pandemic? Seroprevalence of SARS-CoV-2 infection in a North region of Portugal during 3rd lockdown


  • Paula M. Carvalho School of Pharmacy, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal
  • Sandra C. Soares Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal
  • Ana R. Castro Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal




SARS-CoV2 infection, Seroprevalence, Portugal, Public health, Antibody response, COVID-19


Background: Serological studies of antibody prevalence in response to infection with the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are useful to monitor the epidemic progression of the disease and to evaluate infection rates. In this study, we estimated the prevalence of anti-SARS-CoV-2 antibodies (IgM and IgG) in a Portuguese sub-district, during National lockdown - January-March 2021.

Methods: In the seroepidemiological survey participants were tested for SARS-CoV-2 antibodies (IgM and IgG), in blood samples. The estimated seroprevalence and results were stratified by age, gender, education, occupational exposure, symptoms and previous SARS-CoV-2 infection.

Results: Seroprevalence was 41.3%, (15.7% IgG positive, 11.6% IgM positive and 14% positive for both). The majority (74%) of the participants were working presentially and did the serological assay because they had either symptoms / positive contact (90%) or had a previous positive antigen test (36%). From all the seropositive cases only 44% were symptomatic. Our results show that seroprevalence of SARS -CoV-2 is high in the North, in parallel with the National Surveillance System. Seroprevalence was higher in woman than man and in adults older than 21. Almost all the people with symptoms or a positive contact had a positive test and were working at their regular places of work reflecting the danger of occupational exposure.

Conclusions: These results suggest that, between January and March 2021, the restriction conditions were effective but unable to stop SARS-CoV-2 epidemic. It is essential to assess SARS-CoV-2 seroprevalence to monitor population immunity and if it lasts, specially from new COVID 19 variants.


World Health Organization. 2020. https://www.who.int/director-general/speeches/de tail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. 2020. Accessed on 24th May, 2021.

Instituto Nacional Estatistica. https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=473839541&DESTAQUESmodo=2&xlang=pt, 2021. Accessed on 20th May, 2021.

Diário da República (DR). https:// data.dre.pt/eli/dec-lei/6-A/2021/01/14/p/dre, 2021. Accessed on 26th May 2021.

Ricoca-Peixoto V, Vieira A, Aguiar P, Carvalho C, Thomas DR, Abrantes A. Initial Assessment of the Impact of the Emergency State Lockdown Measures on the 1st Wave of the COVID-19 Epidemic in Portugal. Acta Med Por. 2020;33:733-41.

Kislaya I, Gonçalves P, Barreto M, Sousa R, Garcia AC, Matos R, et al. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Acta Med Por. 2021;34:87-94.

Meireles P, Amaro J, Costa JP, Lopes MM, Varandas T, Norton P, et al. Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal. 2021 MedRxiv.

Direção Geral de Saúde. https://covid19.min-saude.pt/wp-content/uploads/2020/12/304_DGS_boletim_20201231-002.pdf, 2020. Accessed on 26th May 2021.

World Health Organization. 2020. WHO-2019-nCoV-SurveillanceGuidance-2020.8-eng.pdf. 2020. Accessed on 15th May 2021.

Instituto Nacional de Estatistica. 2021. https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=491304080&DESTAQUESmodo=2, 2021. Accessed on 24th May 2021.

Peeling R, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology testing in the COVID-19 pandemic response. Lancet. 2020;20:E245-9.

Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JA, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081-90.

World Health Organization. Seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020. Accessed on 19th May, 2021.

Shaaban AN, Peleteiro B, Martins MRO. COVID-19; what is next for Portugal 2020 Front. Public Health. 2020;8:392.

Laires PA, Nunes C. Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health. Acta Med Port. 2020;33:720-5.

Laires PA, Perelman J. The current and projected burden of multimorbidity: a cross sectional study in a Southern Europe population. European Journal of Ageing. 2019;16:181-92.

Peckham H, Gruijter NM, Raine C. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU. Nature Communication. 2020;11:6317.

Gaitens J, Condon M, Fernandes E, McDiarmin M. COVID-19 and essential workers: a narrative review of health outcomes and moral injury Int J Environ Res Public Health. 2021;18:144601.

Pagani G, Conti F, Giacomelli A, Bernacchia D, Rondanin R, Prina A, et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. Journal of Infection. 2020;81:e10-2.

Bourgonje AR, Abdulle AE, Timens W, Hillebrands J-L, Navis GJ, Gordijn SN et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251:228-48.

Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020;157:104833.

Pawelec G and Weng NP. Can an effective SARS-CoV-2 vaccine be developed for the older population? Immun Ageing. 2020;17:8.

Hawkins D. Differential occupational risk for COVID‐19 and other infection exposure according to race and ethnicity. Am J Ind Med. 2020;63:817-20.

Ganghi M, Yokoe DS, Havlir D. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382:2158-60.

Wilmes P, Zimmer J, Schultz J, Glod F, Veiber L, Mombaerts L, et al. SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme. Luxembourg. 2021;4:100056.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su, Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71:2027-34.

Long Q-X, Liu B-Z, Huang A-L. Antibody responses to SARS-CoV-2 in patients with COVID-19 Nature Medicine. 2020;26:845-8.

Okba NMA, Muller MA, Li E, Wang C, Kessel CH, Corman VM et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients. Emerging Infectious Diseases. 2020;26:1478-88.




How to Cite

Carvalho, P. M., Soares, S. C., & Castro, A. R. (2021). What did we learn after the 2020 pandemic? Seroprevalence of SARS-CoV-2 infection in a North region of Portugal during 3rd lockdown. International Journal of Research in Medical Sciences, 9(9), 2568–2572. https://doi.org/10.18203/2320-6012.ijrms20213393



Original Research Articles